Glucocorticoid
Consensus statement on thyroid eye disease focuses on new therapies, individualized care
Individualized care and patient satisfaction are among the areas of emphasis in a new consensus statement on management of thyroid eye disease.
Sarilumab, tapered glucocorticoids improve steroid-resistant polymyalgia rheumatica
PHILADELPHIA — Patients with steroid-resistant polymyalgia rheumatica who received sarilumab and tapered glucocorticoids achieved higher remission rates vs. glucocorticoid taper alone, according to data presented at ACR Convergence 2022.
Bone-safe glucocorticoid dose ‘hard to find’ in rheumatic, musculoskeletal diseases
PHILADELPHIA — A daily glucocorticoid dose higher than 2.5 mg may lead to irreversible bone mineral density loss regardless of intervention with osteoporosis medications, according to data presented at ACR Convergence 2022.
Avacopan, rituximab allow for reduced glucocorticoid use in ANCA-associated vasculitis
SAN DIEGO — In patients with ANCA-associated vasculitis, avacopan and rituximab may offer an alternative to glucocorticoids-based management, according to a presenter at the Congress of Clinical Rheumatology West.
Physical Therapy Awareness Month shines light on therapy for patients with osteoarthritis
October is Physical Therapy Awareness month, and the role of physical therapy in the management of rheumatic diseases, specifically osteoarthritis, is being highlighted in research as well as on social media.
COVID-19 vaccines 87% effective at preventing hospitalization in immunosuppressed patients
Three doses of either the BNT162b2 or mRNA-1273 vaccine are 87% effective at preventing hospitalization due to COVID-19 among patients taking immunosuppressive drugs, according to data published in The Lancet Rheumatology.
‘Our friend and our enemy’: Rheumatologists continue to grapple with steroids
The movement away from long-term steroid use has reached all corners of rheumatology, and for good reason: Extended use of glucocorticoids can be associated with a raft of adverse outcomes.
ACR: Patients on long-term glucocorticoids should receive oral bisphosphonates
Patients receiving long-term glucocorticoids should use oral bisphosphonates to reduce the risk for bone loss and fracture, according to new guidelines currently under peer review from the American College of Rheumatology.
Low-dose prednisolone beneficial in patients with established rheumatoid arthritis
Add-on low-dose prednisolone improves long-term disease activity and progression in senior patients with established rheumatoid arthritis, albeit with an increase in non-severe adverse events, according to data.
Trio of anifrolumab lupus trials show concordant BICLA, SRI(4) responses in most patients
Most patients with systemic lupus erythematosus across a trio of anifrolumab trials demonstrated concordant outcomes on BILAG-based Composite Lupus Assessment and SLE Responder Index responses, according to data.